Hydroxyurea therapy in SS children

Research output: Contribution to journalArticle

Abstract

Children with sickle cell anemia treated with hydroxyurea at 2 years of age maintain Hb F levels above 20% for 4 to 6 years with little hematologic toxicity and no increased risks of infection. Its ability to prevent subclinical organ damage, however, is yet to be proven.

Original languageEnglish (US)
Pages (from-to)2228
Number of pages1
JournalBlood
Volume106
Issue number7
StatePublished - Oct 2005

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Toxicity
Infection
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Hydroxyurea therapy in SS children. / Dover, George J.

In: Blood, Vol. 106, No. 7, 10.2005, p. 2228.

Research output: Contribution to journalArticle

Dover, GJ 2005, 'Hydroxyurea therapy in SS children', Blood, vol. 106, no. 7, pp. 2228.
Dover, George J. / Hydroxyurea therapy in SS children. In: Blood. 2005 ; Vol. 106, No. 7. pp. 2228.
@article{319cfab2f86c46a392f72bfdf5698451,
title = "Hydroxyurea therapy in SS children",
abstract = "Children with sickle cell anemia treated with hydroxyurea at 2 years of age maintain Hb F levels above 20{\%} for 4 to 6 years with little hematologic toxicity and no increased risks of infection. Its ability to prevent subclinical organ damage, however, is yet to be proven.",
author = "Dover, {George J}",
year = "2005",
month = "10",
language = "English (US)",
volume = "106",
pages = "2228",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Hydroxyurea therapy in SS children

AU - Dover, George J

PY - 2005/10

Y1 - 2005/10

N2 - Children with sickle cell anemia treated with hydroxyurea at 2 years of age maintain Hb F levels above 20% for 4 to 6 years with little hematologic toxicity and no increased risks of infection. Its ability to prevent subclinical organ damage, however, is yet to be proven.

AB - Children with sickle cell anemia treated with hydroxyurea at 2 years of age maintain Hb F levels above 20% for 4 to 6 years with little hematologic toxicity and no increased risks of infection. Its ability to prevent subclinical organ damage, however, is yet to be proven.

UR - http://www.scopus.com/inward/record.url?scp=27144512883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144512883&partnerID=8YFLogxK

M3 - Article

VL - 106

SP - 2228

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -